CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2007-04-10): Radioembolization plus chemotherapy "impressive" for colorectal metastases to liver


Radioembolization plus chemotherapy "impressive" for colorectal metastases to liver

Last Updated: 2007-04-10 15:45:15 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Treatment of inoperable liver metastases from colorectal cancer with radioembolization of the tumors using yttrium-90 microspheres, added to standard chemotherapy, is safe, well tolerated and had a 90% response rate in a phase I trial conducted at the University of Oxford, UK.

In the 20-patient trial, Dr. Ricky A. Sharma and colleagues injected resin microspheres containing the beta-emitter yttrium-90 into the hepatic artery, targeting the malignant vasculature.

Patients continued to receive gold-standard chemotherapy with fluorouracil and leucovorin (FOLFOX). Results of the study are published in the March 20th issue of the Journal of Clinical Oncology.

Dr. Sharma told Reuters Health that 18 patients (90%) "showed an objective response to treatment, involving a decrease in the tumour size by at least 50%. The remaining two patients (10%) had stabilization of their disease."

Tumor size decreased sufficiently in two patients "to enable the remaining disease to be removed by surgery," Dr. Sharma added.

"Although this is a small study in 20 patients, the findings are impressive compared to equivalent studies conducted using FOLFOX chemotherapy alone in patients with similar disease," Dr. Sharma continued. "Most importantly, the addition of radioembolization appears to be well-tolerated, thus paving the way for larger studies of this combination."


In fact, an international trial involving over 20 cancer centers in the UK and Australia is currently being developed, Dr. Sharma said. "This trial will study patients with colorectal cancer that has spread to the liver and is not amenable to surgery, who have not previously received chemotherapy for the spread of their disease."

J Clin Oncol 2007;25:1099-1106.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2017 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.